Betaine improved adipose tissue function in mice fed a high-fat diet: A mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 298, Issue 5, 2010, Pages

  Wang, Zhigang ^a,b   Yao, Tong ^a   Pini, Maria ^a   Zhou, Zhanxiang ^c   Fantuzzi, Giamila ^a   Song, Zhenyuan ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c University of Louisville School of Medicine   (United States)

Author keywords

Adipokine; Adipose tissue; Betaine; Endoplasmic reticulum stress; Fatty liver; Insulin resistance

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; BETAINE; CCAAT ENHANCER BINDING PROTEIN; GLUCOSE REGULATED PROTEIN 78; INSULIN; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RESISTIN; STRESS ACTIVATED PROTEIN KINASE;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ENZYME ACTIVATION; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; LIVER PROTECTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BETAINE; DIETARY FATS; ENDOPLASMIC RETICULUM; FATTY LIVER; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL;

EID: 77951468032     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00249.2009     Document Type: Article

References (42)

1. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96: 2711-2717, 2001.
2. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047-9054, 2000.
3. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17: S186-S190, 2002.
4. Barak AJ, Beckenhauer HC, Badakhsh S, Tuma DJ. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res 21: 1100-1102, 1997.
5. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem 37: 911-917, 1959.
6. Carmen GY, Víctor SM. Signaling mechanisms regulating lipolysis. Cell Signal 18: 401-408, 2006.
7. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 8: 575-894, 2004. (Pubitemid 39141144)
8. Craig SA. Betaine in human nutrition. Am J Clin Nutr 80: 539-549, 2004.
9. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006. (Pubitemid 43303974)
10. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 45: 1097-1107, 2007. (Pubitemid 46775771)
11. Graf D, Kurz AK, Reinehr R, Fischer R, Kircheis G, Haussinger D. Prevention of bile acid-induced apoptosis by betaine in rat liver. Hepatology 36: 829-839, 2002.
12. Gregor MG, Hotamisligil GS. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 48: 1905-1914, 2007.
13. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 420: 333-336, 2002. (Pubitemid 35398190)
14. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29: 495-501, 1998.
15. Ji C, Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 124: 1488-1499, 2003. (Pubitemid 36531821)
16. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28: 370-399, 2008.
17. Kathirvel E, Morgan K, French SW, Morgan TR. Betaine reduced insulin resistance and hepatic steatosis, and augments hepatic insulin signaling, in an animal model of NAFLD (Abstract). Hepatology 48: 486A, 2008.
18. Kharbanda KK, Rogers 2nd DD, Mailliard ME, Siford GL, Barak AJ, Beckenhauer HC, Sorrell MF, Tuma DJ. Role of elevated S-adenosyl-homocysteine in rat hepatocyte apoptosis: protection by betaine. Biochem Pharmacol 70: 1883-1890, 2005.
19. Koc H, Mar MH, Ranasinghe A, Swenberg JA, Zeisel SH. Quantitation of choline and its metabolites in tissues and foods by liquid chromatography/ electrospray ionization-isotope dilution mass spectrometry. Anal Chem 74: 4734-4740, 2002.
20. Kosone T, Takagi H, Horiguchi N, Ariyama Y, Otsuka T, Sohara N, Kakizaki S, Sato K, Mori M. HGF ameliorates a high-fat diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 293: G204-G210, 2007. (Pubitemid 47105193)
21. Kwon do Y, Jung YS, Kim SJ, Park HK, Park JH, Kim YC. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr 139: 63-68, 2009.
22. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358: 893-894, 2001.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985. (Pubitemid 15018832)
24. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 50: 722-727, 2000. (Pubitemid 30642806)
25. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Fagà E, Pacini G, De Michieli F, Rabbione L, Premoli A, Cassader M, Pagano G. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42: 1175-1183, 2005.
26. Nair S, Diehl AM, Perrillo RP. Metformin in non-alcoholic steatohepatitis (NASH): efficacy and safety-a preliminary report (Abstract). Gastroenterology Suppl 122: 4, 2002.
27. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20: 23-28, 2004.
28. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008-1017, 2003.
29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007.
30. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313: 1137-1140, 2006.
31. Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 49: 183-190, 2006.
32. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 105: 9793-9798, 2008.
33. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39: 188-196, 2004.
34. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 13: 3540-3553, 2007.
35. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus, Cochrane Database Syst Rev 18: CD006060, 2006.
36. Sakamoto A, Nishimura Y, Ono H, Sakura N. Betaine and homocysteine concentrations in foods. Pediatr Int 44: 409-413, 2002.
37. Song Z, Deaciuc I, Zhou Z, Song M, Chen T, Hill D, McClain CJ. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 293: G894-G902, 2007.
38. Taniguchi CM, Aleman JO, Ueki K, Luo J, Asano T, Kaneto H, Stephanopoulos G, Cantley LC, Kahn CR. The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinasemediated insulin resistance. Mol Cell Biol 27: 2830-2840, 2007.
39. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53: 2169-2176, 2004.
40. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131: 934-1945, 2006.
41. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci USA 103: 10741-10746, 2006.
42. Zeisel SH, Mar MH, Howe JC, Holden JM. Concentrations of choline-containing compounds and betaine in common foods. J Nutr 133: 1302-1307, 2003. (Pubitemid 36548698)